Verismo Therapeutics shared on LinkedIn:
“Verismo Therapeutics is excited to present a poster at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting 2026, highlighting preclinical data from its KIR-CAR platform.
Verismo’s poster presentation will highlight the in vivo profile of mesothelin-targeted multi-chain KIR-CAR T cells (the platform behind SynKIR™-110, currently in the STAR-101 Phase 1 Clinical Trial, NCT05568680).
- Location: Phoenix Convention Center, Poster Hall, Phoenix, AZ
- Abstract Number: 253
- Title: Mesothelin-targeted Multi-Chain Killer Immunoglobulin Receptor (KIR)-based CAR T Reduces Exhaustion, Cytokine Release, and Enhances Safety Profile in vivo vs CD28 or 41BB single-chain CAR T
- Presenting Author: Nora Yucel, Ph.D., Principal Scientist, Verismo Therapeutics
- Session: Poster Hall
- Presentation Time: Friday, November 6, 2026: 10 AM – 2 PM, 5 – 7 PM MT.
Register for SITC 41st Annual Meeting 2026 here.”
Society for Immunotherapy of Cancer (SITC), added:
“We are looking forward to your poster presentation! See you in Phoenix!”
Read more articles about SITC on OncoDaily.